Skip to content
Search

Latest Stories

Is Vitamin C a game changer for Covid-19?

A major science review published in Nutrients shows vitamin C can save the lives of those badly infected with Covid-19 and make symptoms of milder infections less severe.

Results from more than a 100 studies, including a gold-standard RCT (Randomised Controlled Trial) which showed that vitamin C could cut the death rate of patients in intensive care units by 68 per cent. The patients got vitamin C or sterile water from a drip.


A similar trial comparing a steroid drug (dexamethasone) with a placebo in June was hailed as a success. It reduced deaths by just 3 per cent.

The amount of vitamin C needed to the reduce deaths and time on ventilators in ICUs ranged between 6 and 24 grams a day, says lead author and nutritionist Patrick Holford.

Another author, Dr Anitra Carr, explained why such high doses are needed. "When you get a severe infection, your body uses up vitamin C at a much faster rate in order to support the immune system.

"That’s because humans are one of the few animals that can’t make vitamin C, so we can’t increase supplies when needed." Dr Carr, who is associate professor at the University of Otago in New Zealand, points out that only animals that don't make vitamin C – primates, guinea pigs and bats – are susceptible to Covid-19.

Further support for using high doses come from studies showing that most Covid-19 patients coming into ICUs already have very low vitamin C levels.

"Their levels are often undetectable," says co-author Professor Paul Marik, chief of Critical Care Medicine at Eastern Virginia Medical School. "That’s what you see in patients with scurvy. This infection induces scurvy. We can predict how likely patients are to survive by their level of vitamin C."

Marik explains that to stop scurvy one needs high doses of vitamin C. It is also vital for damping down the dangerous inflammation that develops as Covid-19 progresses and can be fatal.

By combining vitamin C with steroids and anticoagulant drugs Professor Marik and others have reduced the death rate of critical ill Covid-19 patients to less than five per cent. “No-one is dying who doesn’t have both a pre-existing end stage disease and is over 85 years old,” he says.

Another author on the paper is David Smith, emeritus professor of pharmacology at the University of Oxford who is presenting the evidence to the National Institute for Clinical Evidence (NICE).

Philip Calder from the University of Southampton, who is professor of nutritional immunology within medicine is talking about the paper to the Nutrition Society today, to inform members of the UK’s Scientific Advisory Committee of Nutrition (SACN) who advise government on policy.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less